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Abstract
 
Kaposi’s sarcoma–associated herpesvirus interleukin-6 (vIL-6) is a structural and functional homo-
logue of the human cytokine IL-6 (hIL-6). hIL-6 and vIL-6 exhibit similar biological functions
and both act via the gp130 receptor subunit to activate the Janus tyrosine kinase (JAK)1 and
signal transducer and activator of transcription (STAT)1/3 pathway. Here we show that vIL-6
is N-linked glycosylated at N78 and N89 and demonstrate that N-linked glycosylation at site
N89 of vIL-6 markedly enhances binding to gp130, signaling through the JAK1-STAT1/3
pathway and functions in a cytokine-dependent cell proliferation bioassay. Although hIL-6 is
also N-glycosylated at N73 and multiply O-glycosylated, neither N-linked nor O-linked glycosyla-
tion is necessary for IL-6 receptor 
 
 
 
–dependent binding to gp130 or signaling through JAK1-
STAT1/3. As distinct from vIL-6, unglycosylated hIL-6 is as potent as glycosylated hIL-6 in
stimulating B cell proliferation. These findings highlight distinct functional roles of N-linked
glycosylation in viral and cellular IL-6.
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Introduction
 
Kaposi’s sarcoma–associated herpesvirus (KSHV), herpesvirus
8, is a 
 
  
 
herpesvirus etiologically associated with Kaposi’s
sarcoma, multicentric Castleman’s disease, and primary
effusion lymphomas (PELs). Viral IL-6 (vIL-6), a structural
and functional homologue of human IL-6 (hIL-6), is one
of several homologues of cellular chemokines and cytokines
encoded by KSHV (1). Although vIL-6 exhibits only
24.8% amino acid identity and 62.2% amino acid similarity
with hIL-6 (2), it mimics a number of hIL-6 activities such
as stimulating IL-6–dependent B cell line growth (3) and
activating the Janus tyrosine kinase (JAK)1 and signal trans-
ducer and activator of transcription (STAT)1/3 pathway in
HepG2 cells (4). hIL-6 is expressed by a number of cell
types including B and T lymphocytes, monocytes, fibro-
blasts, keratinocytes, bone marrow stromal cells, endothelial
cells, and astrocytes. The wide range of biological activities
attributed to hIL-6 includes the proliferation of lymphocytes
and stem cells, differentiation of B cells and osteoclasts, induc-
tion of acute phase proteins in hepatocytes, and promotion
of neuronal regeneration (5). hIL-6 serves as a growth factor
for multiple myeloma and plasmacytoma cells (6). vIL-6 is
expressed in KSHV-infected B cells and endothelial cells
and induces proliferation, angiogenesis, and hematopoiesis
in IL-6–dependent cell lineages (2, 7). vIL-6 can serve as an
autocrine growth factor for PEL cell lines (8). Expression of
vIL-6 accelerates hematopoiesis in mice and induces vascular
endothelial growth factor, a factor implicated in PEL and
Kaposi’s sarcoma pathogenesis (9). However, the precise
function of vIL-6 in KSHV pathogenesis is not well under-
stood. vIL-6 may act as an antiapoptotic factor for survival
of KSHV-infected cells and/or promote the proliferation
of KSHV-infected cells or potential host cells.
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Despite similarities in their global structures, hIL-6 and
vIL-6 differ in their mode of receptor usage (10–12). vIL-6
and hIL-6 share with other cytokines, such as ciliary neu-
rotrophic factor, leukemia inhibitory factor, oncostatin M,
cardiotropin-1, and IL-11, the use of a gp130 receptor for
signal transduction (13). Although both cellular IL-6 and
vIL-6 bind gp130, the common signal transducing receptor
subunit for the IL-6–type family of cytokines, hIL-6 re-
quires a coreceptor, IL-6R
 
 
 
, for the assembly of a 2:2:2
hexameric signaling complex. Cytokines such as ciliary
neurotrophic factor, leukemia inhibitory factor, oncostatin
M, and IL-11 also require a specific coreceptor (13). In
contrast, vIL-6 directly binds gp130 and does not require
IL-6R
 
  
 
for signal transduction (7, 12). Cytokine binding to
gp130 causes JAKs to phosphorylate STATs, which dimer-
ize and translocate to the nucleus, where they bind specific
enhancer sequences to stimulate or repress transcription of
target genes. IFN-
 
  
 
produced in response to KSHV infec-
tion specifically down-regulates IL-6R
 
 
 
, making it difficult
for hIL-6 to interact with its gp130 receptor (14). Because
vIL-6 binds directly to the signaling gp130 receptor with-
out first binding to IL-6R
 
 
 
, vIL-6 can exerts its prolifera-
tive effects on B cells without being affected by IFN-
 
 
 
.
This study explores the hypothesis that differences in bi-
ological activity and receptor usage of cellular IL-6 and
vIL-6 could be explained by differences in glycosylation of
the two cytokines. Many cytokines are posttranslationally
modified by the addition of sugar groups, which have the
capacity to affect their biological function in a number of
ways such as protein stability, protein secretion, receptor
interaction, and subsequent downstream biological activity
(15). Here we demonstrate that vIL-6 is glycosylated at two
residues, N78 and N89. N-linked glycosylation of one of
these residues, N89, is required for optimal gp130 receptor
binding, JAK/STAT signaling, and stimulation of B cell
proliferation. hIL-6 is known to be O- and N-linked gly-
cosylated (16), but the functional role of the modification
was unknown. We find that hIL-6 is N-glycosylated at one
residue, N73, and O-glycosylated at T166 and T170/
T171, but these glycosylations do not affect binding to the
signaling receptor gp130, JAK/STAT activation, or B cell
proliferation. These novel results show that a virally en-
coded cytokine such as IL-6 distinguishes itself from its cel-
lular homologue through the functional importance of
N-linked sugars.
 
Materials and Methods
 
Cell Culture and Transfections.
 
HKB5/B5 is a hybrid cell line
(provided by M.-S. Cho, Bayer Corp., Berkeley, CA) from fu-
sion of Burkitt lymphoma–derived HH514-16 cells with 293 hu-
man embryonic kidney cell line. HKB5/B5 was used for transient
transfections to produce mammalian-derived cellular IL-6 and
vIL-6. Cells were grown in RPMI 1640 medium supplemented
with 5% FCS at 37
 
 
 
C in 5% CO
 
2
 
. Optimal transfection condi-
tions of HKB5/B5 cells were achieved using the DMRIE-C re-
agent (Invitrogen; reference 17). To produce N-linked unglyco-
sylated forms of vIL-6 and hIL-6, 0.2 or 1.0 
 
 
 
g/ml tunicamycin
(TM) was added to the growth media. To produce O-linked un-
glycosylated forms of hIL-6, 1.0 
 
 
 
g/ml monensin was used. Cul-
ture supernatants and cell extracts were prepared 48 h after trans-
fection. B9.11, an IL-6–dependent mouse plasmacytoma cell line
(18), and DS-1, an IL-6–dependent human B cell line (19), were
used to measure IL-6 activity. These cells were maintained in
RPMI 1640 medium supplemented with 5% FCS and 1 ng/ml
hIL-6 (R&D Systems).
 
Plasmid Constructions.
 
vIL-6 encoded in KSHV ORF K2 was
generated by PCR from genomic cellular DNA preparations of
PEL cell lines BC1, BC-3, and HHB2 (20). The PCR products
contained flanking AseI and XhoI sites. Purified PCR products
were cloned into the prokaryotic expression vector pET22
(Novagen) using the restriction sites NdeI and XhoI. vIL-6 PCR
products were also cloned into the eukaryotic vector pcDNA3.1
(Invitrogen) using the BamHI and XhoI sites. hIL-6 cDNA was
cloned into the EcoRI site of the pcDNA3.1 plasmid vector. Gly-
cosylation site mutants of vIL-6 and hIL-6 were generated using a
QuikChange site-directed mutagenesis kit (Stratagene). The vIL-6
and hIL-6 genes in all clones were sequenced in their entirety.
 
Bacterial Expression of vIL-6.
 
Each clone was transformed
into BL21(DE3) cells. In all purifications, fresh transformants
were grown overnight, culture was incubated at 37
 
 
 
C until the
OD 600 was 0.6–0.7, and cells were induced for 2 h using 1
mM IPTG. Cells were pelleted, resuspended in 40 ml buffer A
(5 mM imidazole, 500 mM NaCl, 20 mM Tris, pH 7.9), soni-
cated three times for 15 s, and centrifuged in a SW28 rotor at 20 K
for 15 min. The pellet was resuspended in buffer A with 6 M
urea, sonicated twice, and placed on ice for 1 h. The supernatant
was loaded on a Ni
 
   
 
agarose column (QIAGEN). The column
was washed with buffer A and buffer B (60 mM imidazole, 500
mM NaCl, 20 mM Tris, pH 7.9). The protein was eluted from
the column with a step gradient of 0.1–1 M imidazole in 1-ml
fractions. The fractions were dialyzed in RPMI medium for 2 h,
aliquoted, and stored at 
 
 
 
80
 
 
 
C. The purified bacterial vIL-6
protein samples were then analyzed by Western blot using an
anti-KSHV IL-6 polyclonal rabbit antisera. The Immunization
Service of the Yale Animal Resources Center hyperimmunized
rabbits with the KSHV IL-6 peptide (PDVTPDVHDK) conju-
gated to KLH.
 
Western Blot Analysis.
 
Extracts were prepared from trans-
fected HKB5/B5 cells grown in culture for 48 h. A total of 2 
 
 
 
10
 
6 
 
cells were resuspended in 100 
 
 
 
l SDS sample buffer and soni-
cated for 15 s. Samples were boiled for 5 min and electropho-
resed through a 10% polyacrylamide gel. Cell extracts loaded in
the Western blots consisted of 
 
 
 
0.5 
 
  
 
10
 
6 
 
transfected HKB5/B5
or HepG2 cells. For vIL-6 or hIL-6 protein in HKB5/B5 trans-
fectant supernatants, 
 
 
 
10 ng protein was loaded. A 1:200 dilu-
tion of vIL-6 rabbit polyclonal antiserum for vIL-6 protein or
1 
 
 
 
g/ml hIL-6 goat polyclonal antibody (R&D Systems) fol-
lowed by a 1:200 dilution of a rabbit anti–goat Ig bridge (Sigma-
Aldrich) was used for vIL-6 or hIL-6 protein detection, respec-
tively. Immunoreactive bands were detected with 
 
125
 
I-labeled
protein A and autoradiography. For the detection of STAT1 pro-
tein and its phosphorylated form, antibodies sc-417 and sc-8394,
respectively, were used (Santa Cruz Biotechnology, Inc.).
 
ELISA for vIL-6 or hIL-6.
 
To detect vIL-6 by ELISA, wells
were coated with 2 
 
 
 
g/ml protein A agarose-purified Ig fraction
of rabbit antiserum to vIL-6 diluted in 100 
 
 
 
l coating buffer (0.1 M
carbonate, pH 9.5). Plates were incubated at 4
 
 
 
C overnight.
The wells were washed three times with PBS containing 0.05%
(vol/vol) Tween and blocked with 10% FCS in PBS for 3 h at
room temperature. After additional washes, serially diluted cul- 
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ture supernatants were added. Purified 
 
Escherichia coli
 
–derived
vIL-6 was used for generating a standard curve. Samples were in-
cubated overnight at 4
 
 
 
C. After further washes, 100 
 
 
 
l biotin-
ylated anti-KSHV IL-6 rabbit antiserum at 2 
 
 
 
g/ml was added for
1 h at room temperature. After PBS/Tween washes, streptavidin
conjugated to horseradish peroxidase (HRP; Zymed Laborato-
ries) at a dilution of 1:3,000 in FCS blocking buffer for 30 min
was added. After 10 washes in PBS/Tween, peroxidase activity
was detected by adding 50 
 
 
 
l/well tetramethylbenzidine substrate
reagent (BD Biosciences). Reaction was stopped using 50 
 
 
 
l 2N
H
 
2
 
SO
 
4
 
. Absorbances were read at 450 nm using a Coulter
MR5000 ELISA reader (Dynatech). To detect hIL-6, 2 
 
 
 
g/ml
polyclonal anti–hIL-6 goat antibody (R&D Systems) was used as
the capturing antibody and 0.5 
 
 
 
g/ml monoclonal anti–hIL-6
mouse antibody was used as the detecting antibody (R&D Sys-
tems) followed by the secondary antibody donkey anti–mouse
IgG HRP (Jackson ImmunoResearch Laboratories). Recombi-
nant hIL-6 (R&D Systems) was used as standard.
 
ELISA for Binding of IL-6 to gp130.
 
ELISA plates were
coated with soluble gp130 (R&D Systems) at 625 ng/ml in car-
bonate buffer overnight. After washing with PBS/Tween and
blocking with PBS/10% FCS for 3 h, wells were loaded with the
vIL-6 supernatants and incubated at 4
 
 
 
C. After washing, vIL-6
that bound to the sgp130 was detected using 100 
 
 
 
l biotinylated
anti-KSHV IL-6 rabbit antiserum at 2 
 
 
 
g/ml and the secondary
reagent of streptavidin conjugated to HRP. For hIL-6, ELISA
plates previously coated with sgp130 were washed and blocked
with PBS/10% FCS before the addition of hIL-6 supernatants
mixed with 625 ng/ml sIL6-R
 
  
 
(R&D Systems). After overnight
incubation at 4
 
 
 
C and multiple washings, bound hIL-6 was de-
tected with 2 
 
 
 
g/ml polyclonal anti–hIL-6 goat antibody and
donkey anti–goat IgG HRP followed by chromogenic substrates.
 
B9.11 and DS-1 Cell Proliferation Assays.
 
B9.11 or DS-1 cells
were washed three times in RPMI 1640 medium without IL-6.
Cells were plated at 4 
 
  
 
10
 
4 
 
cells per 100-
 
 
 
l well in the presence
or absence of vIL-6 and hIL-6 preparations. Recombinant bacte-
rial vIL-6 was purified as described above. Purified recombinant
bacterial hIL-6 was purchased from R&D Systems. Recombinant
forms of both cytokines were expressed in HKB5/B5 cells. After
2 (B9.11) or 4 d (DS-1) of culturing in the presence of serially di-
luted IL-6 samples, cells were pulsed with 1 
 
 
 
l (
 
3
 
H) tritiated thy-
midine for 12–16 h. Proliferation of cells was determined by
thymidine incorporation using a 96-well cell harvester and a
 
 
 
-scintillation counter. B cell proliferative responses were ex-
pressed as mean [
 
3
 
H]thymidine incorporation (cpm) 
 
  
 
standard
errors of triplicate cultures.
 
Luciferase Assay.
 
Transient transfections were performed in
HepG2 cells using transfection reagent DMRIE-C. Cells were
seeded in six-well plates at 1–2 
 
  
 
10
 
6 
 
cells/well in RPMI 1640
containing 10% FCS 24 h before transfection. After culture su-
pernatants were removed, the adherent HepG2 cells were trans-
fected with DMRIE-C reagent premixed with the reporter plas-
mids pGAS/Luc or pLuc in OPTI-MEM medium (Invitrogen)
for 4 h. Cells were incubated for 48 h before treatment with vIL-6
and hIL-6 preparations for another 6 h. Cell lysates were pre-
pared by extraction with 200 
 
 
 
l lysis buffer from the Luciferase
Reporter Gene Assay (Roche) and luciferase activities were mea-
sured using a Lumat luminometer (LB9501; Roche) for 10 s.
 
Online Supplemental Material.
 
Fig. S1 demonstrates that un-
glycosylated hIL-6 expressed in 
 
E. coli
 
, unglycosylated hIL-6 pro-
duced in mammalian cells (through quadruple mutagenesis and
use of glycosylation inhibitors), and fully glycosylated hIL-6 pro-
teins have similar biological potency in stimulating B9.11 cell
proliferation. Fig. S1 is available at http://www.jem.org/cgi/
content/full/jem.20031205/DC1.
 
Results
 
Differences in KSHV IL-6 Expressed in E. coli and Mamma-
lian Cells.
 
To study the function of KSHV IL-6, the pro-
tein was prepared from both bacterial and mammalian
sources. vIL-6 was cloned with a six-residue histidine tag
into the pET-22 vector and purified from 
 
E. coli
 
 using a
nickel column. vIL-6 was also cloned into the mammalian
vector pcDNA3.1 and expressed in human HKB5/B5 cells.
Western blot analysis using polyclonal rabbit antiserum to
vIL-6 revealed differences in electrophoretic mobility of
vIL-6 depending on the source of the protein. There were
three major immunoreactive protein products present in
extracts of HKB5/B5 cells transfected with vIL-6 (Fig. 1 A,
lane 2). The largest and most abundant of these products,
Figure 1. Comparison of vIL-6 expressed in E. coli and in eukaryotic
cells. (A) Comparison of electrophoretic mobility of vIL-6 from various
sources. An immunoblot reacted with polyclonal rabbit antibody to vIL-6.
Lane 1, extract of HKB5 cells transfected with pcDNA3.1; lane 2, extract
of HKB5/B5 cells transfected with pcDNA3.1/vIL-6; lane 3, purified
vIL-6 expressed in E. coli; lane 4, extracts of HHB2 cells, a KSHV  PEL
cell line; lane 5, extract of HH514-16 (clone16), an EBV  KSHV  Burkitt
lymphoma cell line. (B) Comparison of biological activity of vIL-6–
expressed mammalian cells or E. coli in a B9.11 cell proliferation assay.
B9.11 cells were incubated with supernatants of HKB5/B5 cells trans-
fected with pcDNA3.1 or pcDNA3.1/vIL-6 (BC-1). B9.11 cells were
also incubated with vIL-6 from three KSHV strains cloned in pET22,
expressed in E. coli, and purified on Ni   columns. The concentration of
vIL-6 expressed in eukaryotic cells was 25 ng/ml. The concentration of
vIL-6 expressed in E. coli varied from 17 to 147  g/ml. 
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28 kD, comigrated with vIL-6 expressed during the
KSHV lytic cycle in HHB2 cells, a KSHV-infected PEL
cell line (Fig. 1 A, lane 4). An EBV-infected Burkitt lym-
phoma cell line contained no immunoreactive vIL-6 (Fig.
1 A, lane 5). 
 
E. coli
 
–produced His-tagged vIL-6 protein
(Fig. 1 A, lane 3) showed one predominant polypeptide,
 
 
 
21 kD, which was slightly larger in molecular weight
than the smallest form of vIL-6 present in human cells (Fig.
1 A, lane 2). We postulated that the electrophoretic mobil-
ity of the 
 
E. coli
 
–expressed vIL-6 could be accounted for by
an unmodified form of the protein containing additional
residues from the histidine tags.
KSHV IL-6 proteins derived from 
 
E. coli
 
 or mammalian
cells were tested for their ability to stimulate the prolifera-
tion of IL-6–dependent B9.11 cell line using a thymidine
incorporation assay. vIL-6 secreted from the HKB5/B5
mammalian cell line potently activated B9.11 cell prolifera-
tion (Fig. 1 B). Purified vIL-6 proteins derived from three
different KSHV strains expressed in 
 
E. coli
 
 only minimally
stimulated the B9.11 cells, even though vIL-6 purified
from 
 
E. coli
 
 contained 
 
 
 
1,000-fold more protein. The ad-
dition of vIL-6 made in human cells to vIL-6 produced in
bacteria restored maximum proliferation of B9.11 cells, in-
dicating that poor response to bacterial-derived vIL-6 was
not due to toxicity (unpublished data). These findings sug-
gested that posttranslational modifications of vIL-6 that oc-
curred in human cells, but not in 
 
E. coli
 
, might be impor-
tant for its biological function.
 
N-linked Glycosylation Site Mutants of KSHV IL-6.
 
The
vIL-6 protein has two potential N-linked glycosylation
consensus sites, as represented by Asn-X-Ser/Thr, where
X can be any amino acid. These are located at N78 and
N89. The three forms of vIL-6 observed in HKB5/B5
cells (Fig. 1 A, lane 2) could be explained by forms of the
protein with both sites, one site, or no sites glycosylated.
To explore this possibility, site-directed mutants, N78K
and N89K, and the double mutant N78K/N89K, were
generated. These mutations retain a functional amine
group but cannot be glycosylated. The electrophoretic
mobility of the mutants was compared with wild-type vIL-6
in cell extracts and supernatants of transfected HKB5/B5
cells (Fig. 2). Wild-type vIL-6 migrated more slowly, at 28
kD, than either single N-linked glycosylation site mutant,
which migrated at 
 
 
 
25 kD. The double mutant that
lacked both N-linked glycosylation sites migrated fastest at
 
 
 
22 kD. These findings were most consistent with
N-linked glycosylation of both residues in the wild-type
protein. All the mutant vIL-6 proteins were produced in
amounts approximately equal to wild-type and were se-
creted in equal amounts (see Fig. 5 C).
 
Effect of TM on Electrophoretic Mobility of KSHV IL-6 Pro-
tein.
 
To confirm that the differences in electrophoretic
mobility of wild-type vIL-6 and mutant forms of vIL-6
were the result of N-linked glycosylation, the proteins
were expressed in HKB5/B5 cells treated with TM (Fig.
3). When wild-type vIL-6 was produced in the presence of
TM, the mobility of the vIL-6 polypeptide shifted from a
predominantly 28-kD form (Fig. 3, lane 2) to a 22-kD
form (Fig. 3, lanes 3 and 4), which comigrated with the
N78K/N89K double mutant (Fig. 3, lane 5). TM treat-
ment of cells expressing the single glycosylation site mu-
tants, N78K and N89K, resulted in a change in electro-
Figure 2. Comparison of electrophoretic mobility of wild-type and
N-linked glycosylation site mutants of vIL-6. Wild-type vIL-6 and
N-linked glycosylation site mutants (N78K, N89K, and N78K/N89K) were
expressed in HKB5/B5 cells. Immunoblots were probed with polyclonal
antibodies to vIL-6. (A) Cell extracts. (B) Culture supernatants concentrated
 13-fold by dialysis against polyethylene glycol. Arrows indicate doubly,
singly, and unglycosylated forms of the protein.
Figure 3. Effect of TM on electrophoretic mobility of vIL-6. HKB5/
B5 cells were transfected with wild-type or N-linked glycosylation site
mutants of vIL-6. The cells were untreated (lanes 2, 5, 8, 12, and 15) or
received 0.2 (lanes 3, 6, 9,13, and 16) or 1.0  g/ml (lanes 4, 7, 11, 14,
and 17) TM. Lanes 1 and 10, HH-B2 cell extracts; lanes 2–4, vIL-6; lanes
5–7, N78K/N89K; lanes 8, 9, and 11, pcDNA3; lanes 12–14, N78K;
lanes 15–17, N89K. 
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phoretic mobility from a predominant 25-kD form to the
22-kD form. TM treatment did not affect the electro-
phoretic mobility of vIL-6 expressed by the mutant N78K/
N89K (Fig. 3, lanes 5–7). These results showed that in
wild-type vIL-6, both N78 and N89 were N-linked glyco-
sylated. The predominant 28-kD protein represents the
doubly N-linked glycosylated form of vIL-6, the 25-kD
protein represents the two singly N-linked glycosylated
species, and the 22-kD protein represents a non-N–linked
glycosylated form of vIL-6 protein.
 
Requirement of N89 in KSHV IL-6 for Optimal Function in
B9.11 Cytokine-dependent Cell Proliferation Assay.
 
To de-
termine whether specific N-linked glycosylation of vIL-6
was required for its biological function and could explain
the nonoptimal function of nonglycosylated, bacterially
produced vIL-6, supernatants from HKB5/B5 cells trans-
fected with different vIL-6 N-linked glycosylation mutant
constructs containing equal amounts of immunoreactive
vIL-6 were assessed for their capacity to stimulate B9.11
cell growth. By comparison to wild-type vIL-6 and the
N78K mutant, the N89K and N78K/N89K double mu-
tants of vIL-6 were 16-fold impaired in their ability to
stimulate proliferation of B9.11 cells (Fig. 4). This result
suggested that N-linked glycosylation at site N89 was im-
portant for vIL-6 function, whereas N78 site was not es-
sential. Another interpretation of this result was that the
N89K mutation created a form of vIL-6 that inhibited
B9.11 cell proliferation. Experiments were performed in
which N89K vIL-6 protein was combined with wild-type
vIL-6 to determine whether N89K acted as a dominant
negative mutant. An additive effect on B9.11 cell prolifer-
ation was observed when N89K vIL-6 supernatants were
mixed with wild-type vIL-6 (unpublished data). Similarly,
HKB5/B5 cells were cotransfected with N89K vIL-6
and wild-type vIL-6 plasmids to determine if N89K mu-
tant vIL-6 could block wild-type vIL-6 intracellularly.
Results of B9.11 cell proliferation assays using superna-
tants from the cotransfected cells showed no inhibition of
wild-type vIL-6 activity by the mutant N89K form (un-
published data).
Site-directed mutants N78Q, N89Q, and N78Q/N89Q
of vIL-6 were also produced in HKB5/B5 cells. vIL-6 en-
coded by these mutants were secreted in equal amounts,
but the N89Q and double mutant forms were again 16-
fold impaired in stimulating proliferation of B9.11 cells
(unpublished data). Wild-type and N-linked glycosylation
site mutants of vIL-6 were also tested on DS-1, a human B
cell line that is cytokine dependent (19). In this assay, the
N89K and N78K/N89K double mutant were impaired in
their ability to stimulate DS-1 cells by comparison to wild-
Figure 4. N89 of KSHV IL-6 is required for optimal function in a B9.11
cell cytokine–dependent proliferation assay. Two-fold serially diluted
supernatants, containing 25 ng/ml vIL-6 protein as determined by vIL-6–
specific ELISA, derived from HKB5/B5 cells transfected with plasmids
encoding wild-type vIL-6, or mutants N78K, N89K, and N78K/N89K
were assessed for their capacity to stimulate proliferation of B9.11 cells.
Cells were pulsed with tritiated thymidine from 48 to 64 h after addition of
the supernatants, and radioactivity incorporation (cpm) was determined.
Figure 5. Comparison of binding to gp130 by wild-type and
N-linked glycosylation site mutants of vIL-6. (A) Comparison of bind-
ing to sgp130 by vIL-6 expressed in HKB5/B5 cells and in E. coli. Solu-
ble gp130 was coated on plastic plates. Serial dilutions starting at 20 ng/
ml purified E. coli–derived wild-type vIL-6 from three different KSHV
strains and HKB5/B5-derived wild-type vIL-6 were assessed for binding
to gp130 by ELISA. (B) Comparison of binding to sgp130 by wild-type
vIL-6 and N-linked glycosylation site mutants. Supernatants from trans-
fected HKB5/B5 cells containing equal amounts of vIL-6 or its mutants
were assessed for their capacity to bind to sgp130 by an ELISA. (C) Assay
for the amount of immunoreactive vIL-6 added to sgp130 in the exper-
iment shown in Fig. 5 B. Plates were coated with purified polyclonal
rabbit anti–vIL-6 IgG. In experiments shown in A, B, and C, the
amount of vIL-6 bound was detected with biotinylated polyclonal rabbit
antibody to KSHV IL-6.N-linked Glycosylation of Viral and Human IL-6 508
type and N78K vIL-6 to a similar extent as they were in
the B9.11 cell assay (unpublished data).
KSHV IL-6 N-linked Glycosylation Site Variants Are Im-
paired in Binding to sgp130. The human homologue of
IL-6 must bind to the high affinity   subunit of IL-6R (IL-
6R ) before it engages the signal-transducing   subunit
gp130 (13). However, vIL-6 can directly bind and trigger
the gp130 receptor independent of IL-6R  (21). Various
forms of vIL-6 were studied for binding to sgp130 using an
ELISA assay we developed (Fig. 5). Using equal amounts of
immunoreactive vIL-6, the cytokine cloned from three dif-
ferent KSHV  cells lines (BC1, BC3, and HH-B2) ex-
pressed in bacterial cells, which exhibited relatively poor
proliferative ability to stimulate B9.11 cells (Fig. 1 B), was
also impaired in its capacity to bind sgp130 when compared
with its mammalian cell–derived counterpart (Fig. 5 A).
Mutants N89K and N78K/N89K expressed in human cells
were approximately threefold impaired in binding sgp130
in comparison to wild-type and N78K vIL-6 (Fig. 5 B).
Wild-type vIL-6 and the mutants used in the binding assays
contained equal amounts of immunoreactive vIL-6 (Fig. 5
C). These experiments provided a correlation between the
ability of the mutants to bind the sgp130 receptor and the
capacity to stimulate proliferation of cytokine-dependent
B9.11 cells.
TM Inhibits Binding to sgp130 and Functional Activity of
KSHV IL-6. To establish whether the impaired binding
of the N89K and N78K/N89K mutants was due to alter-
ations of glycosylation, we compared binding to sgp130 of
wild-type vIL-6 expressed in the presence or absence of
TM (Fig. 6). The effect of TM on the secreted vIL-6 prep-
aration used for the experiments was to change it from a
fully glycosylated to an unglycosylated form (Fig. 6, A and
B). TM slightly reduced the amount of immunoreactive
vIL-6 that was secreted, however, equal amounts of vIL-6
were used for the binding studies (Fig. 6 C). vIL-6 ex-
pressed in the presence of TM bound to sgp130 approxi-
mately two- to threefold less well than wild-type vIL-6
(Fig. 6 D). The extent of impairment in binding of vIL-6
expressed in the presence of TM (Fig. 6 D) was similar to
the impairment in binding by the N89K and N78K/N89K
mutants (Fig. 5 B). TM added in the binding assay to wild-
type vIL-6 expressed in the absence of the inhibitor did not
affect binding of vIL-6 to gp130 (Fig. 6 D).
The decrease in binding to sgp130 of vIL-6 expressed in
the presence of TM was reflected in a decrease in the ca-
pacity of vIL-6 to stimulate proliferation of B9.11 cells
(Fig. 6 E). Culture supernatants of HKB5/B5 cells treated
with TM were toxic to the B9.11 cells, however, this tox-
icity was eliminated by diluting the supernatant at 1:120.
Therefore, we compared the biologic activity of vIL-6 and
vIL-6/TM in concentrations of 250 and 125 pg/ml (Fig. 6
E). At these concentrations, vIL-6/TM was approximately
two- to threefold less active than vIL-6 produced in the ab-
sence of TM. The addition of wild-type vIL-6 to vIL-6/
TM restored wild-type activity, indicating that there was
no residual toxicity in the TM-treated samples.
Diminished STAT Protein Activation by N-linked Glycosyla-
tion KSHV IL-6 Mutants. Cellular and KSHV IL-6 ho-
mologues exert their activity by inducing oligomer forma-
tion of gp130 transmembrane signaling protein (22).
These oligomers recruit JAK proteins, which phosphory-
late the STAT family of transcription factors leading to
their translocation to the nucleus for gene activation. We
studied the impact of the N-linked glycosylation site mu-
tants on the JAK/STAT signaling pathway by means of a
reporter assay in which luciferase expression is under the
control of STAT1 binding to three oligomerized IFN- 
response elements (pGAS3/Luc; Fig. 7 A). HepG2 cells
transfected with the pGAS3/Luc or pLuc reporters were
treated with cell culture supernatants containing equal
amounts of vIL-6 or the N-linked glycosylation site mu-
tants for 6 h before luciferase activity was measured.
KSHV IL-6 mutants defective in N-linked glycosylation
at site N89 (N89K and N78K/N89K mutants) were ap-
proximately fourfold reduced in capacity to activate the
Figure 6. Effect of expression of vIL-6 in the pres-
ence of TM on binding to sgp130 and on B9.11 cell
proliferation. (A and B) Electrophoretic mobility of
vIL-6 expressed in HKB5/B5 cells in the absence or
presence of 1.0  g/ml TM. Immunoblots of culture
supernatants (A) or cell extracts (B) were reacted with
polyclonal rabbit antibody to vIL-6. The preparation
shown in A was used for experiments illustrated in
panels C–E. (C) ELISA assay for the amount of vIL-6
present in supernatants of HKB5/B5 cells transfected
with pcDNA3.1 or pcDNA3.1/vIL-6, treated or un-
treated with TM. (D) ELISA assay for binding of vIL-6
to sgp130. In one sample, vIL-6 expressed in the absence
of TM was spiked with TM before assaying its binding
to sgp130. (E) B9.11 assay of vIL-6 expressed in the
absence of TM (solid bars), the presence of TM
(shaded bars), or vIL-6 expressed in the presence of TM
to which untreated vIL-6 was added (hatched bars).Dela Cruz et al. 509
JAK/STAT signaling pathway compared with the activity
of wild-type protein or of the N78K mutant (Fig. 7 A).
Cell lysates of HepG2 cells treated with wild-type and the
N78K mutant contained amounts of phosphorylated
STAT1 protein readily detectable by immunoblotting
(Fig. 7 B). However, the amount of phosphorylated
STAT1 protein in the cell lysates of HepG2 cells treated
with the N78K/N89K vIL-6 mutant was markedly re-
duced (Fig. 7 B). Comparable amounts of STAT1 protein
were present in the cell extracts.
N-linked Glycosylation of hIL-6 Is Not Required for Ac-
tivity. Human cellular IL-6 is known to be N-linked and
O-linked glycosylated, but the functional importance of the
N-linked glycosylation sites is not known. There are two
N-linked glycosylation consensus sites at N73 and N172.
Single (N73K and N172K) and double (N73K/N172K)
mutants of hIL-6 proteins were generated by site-directed
mutagenesis. The wild-type hIL-6 and mutant proteins
produced in HKB5/B5 cells were analyzed on Western
blots (Fig. 8). Unlike vIL-6 in which the large 28-kD form
expressed in HKB5/B5 cells was predominant (Fig. 2 B),
the predominant form of secreted hIL-6 was the broad 21-
kD form. The electrophoretic mobility of N172K mutant
was identical to wild-type. Mutants N73K and N73K/
N172K expressed only the 21-kD form of the protein.
Furthermore, expression of hIL-6 in the presence of TM
(Fig. 8 B) eliminated the 27-kD form. These experiments
indicated that hIL-6 contained a single functional N-linked
glycosylation site at N73.
N-linked glycosylation did not affect the secretion of
cellular IL-6 (Fig. 9 A). Wild-type hIL-6 and the N-linked
glycosylation site mutants bound to sgp130 to a similar ex-
tent, only in the presence of soluble IL6-R  (Fig. 9 B).
N-linked glycosylation site mutagenesis did not alter bind-
ing to sgp130. Furthermore, unlike vIL-6 in which the N89K
mutant cytokine was impaired at stimulating cell prolifera-
tion, the N73K glycosylation site mutation in hIL-6 did
not impair JAK/STAT signaling (Fig. 9 C), B9.11, or DS-1
cell proliferation (Fig. 9 D and unpublished data).
Neither N-linked nor O-linked Glycosylation of hIL-6 Is Re-
quired for Optimal Activity. The majority of hIL-6 mole-
cules are O-glycosylated, whereas a minority are N-glyco-
sylated (Fig. 10, A and B). Through mutagenesis, we found
that O-glycosylation of hIL-6 occurs at sites T166, T170,
and/or T171. A triple mutant of hIL-6 with T to A substi-
tutions at each of these sites showed the absence of the
 22-kD band representing the O-glycosylated form of
Figure 7. STAT signaling by wild-type vIL-6 and N-linked glycosylation
site mutants. (A) HepG2 cells were transfected with pGAS3/Luc, a
STAT1-responsive reporter, or pLuc control reporter. After 48 h, the cells
were treated with 500 (solid bars) or 250  l (open bars) supernatants from
HKB5/B5 cells transfected with wild-type vIL-6, N78K, N89K, N78K/
N89K double mutant, or pcDNA3.1 vector. Luciferase activity was measured
6 h after the addition of supernatants. (B) Immunoblot of extracts of
HepG2 cells treated with vIL-6, N78K, or N78K/N89K double mutant
using antibodies to phosphorylated STAT1 (top) or STAT1 (bottom).
Figure 8. N-linked glycosylation of hIL-6. (A) Electrophoretic mobility
of wild-type hIL-6 and two N-linked glycosylation site mutants of hIL-6
expressed in HKB5/B5 cells. (B) Effect of TM on electrophoretic mobility.
HKB5/B5 cells were transfected with pcDNA3.1/hIL-6 in the presence
of increasing concentrations of TM (lanes 1–3) or no TM (lane 4). Both
immunoblots were reacted with polyclonal antibody to hIL-6.N-linked Glycosylation of Viral and Human IL-6 510
hIL-6 and the presence of the  20-kD unglycosylated
form of the protein (Fig. 10, A and B). This triple mutant
was maximally functionally active in stimulating the IL-6–
dependent B9.11 cells as compared with the wild-type pro-
tein (Fig. 10 D). Moreover, a triple mutant of hIL-6 lack-
ing the three O-glycosylation sites that additionally lacks
the N73 glycan was found to lack all forms of glycosylation
as shown in Fig. 10 A. This fully unglycosylated mutant
form of hIL-6 was equally capable of binding to gp130/IL-
6R  and stimulating proliferation of the B9.11 cells as the
wild-type protein (Fig. 10, C and D). We also made hIL-6
in the presence of monensin, an inhibitor of O-glycosyla-
tion, and TM to produce hIL-6 lacking both O-glycans
and N-glycans (Fig. 10 B, lanes 5 and 6). hIL-6 made in the
presence of these inhibitors was as active as wild-type in
binding gp130/IL-6R  and in stimulating B9.11 cell pro-
liferation (Fig. 10, C and E). Thus, both N-linked and
O-linked glycans on hIL-6 made in mammalian cells are
dispensable for the functional assays we used. Moreover,
the lack of importance of N-glycans in hIL-6 cannot be ac-
counted for by the presence of O-glycans. Recombinant
hIL-6 protein expressed in E. coli bacteria, which are not
known to glycosylate protein, was equally active in stimu-
lating B9.11 cell proliferation as comparable amounts of the
fully glycosylated hIL-6 protein were made in mammalian
cells (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20031205/DC1).
Glycosylated hIL-6 Is More Potent than Glycosylated KSHV
IL-6. To compare the biological activity of cellular IL-6
and vIL-6 that were expressed in mammalian HKB5/B5
cells, we used equal amounts of the fully glycosylated wild-
type hIL-6 and vIL-6 to stimulate B9.11 cell proliferation.
The fully glycosylated form of hIL-6 was  100 times more
potent in stimulating the IL-6–dependent cell growth than
the fully glycosylated form of vIL-6 (Fig. 11).
Discussion
Relative Importance of N-linked Glycosylation of vIL-6 and
hIL-6. This report provides novel information about the
relative importance of N-linked glycosylation modifications
for the function of vIL-6 and cellular IL-6, and represents
the first example of a differential role of N-glycans in the
function of viral and human homologues of the same cyto-
kine. Glycosylated vIL-6 made in eukaryotic cells is at least
1,000 times more potent in stimulating cytokine-dependent
cell proliferation than the unglycosylated form of vIL-6 ex-
pressed in E. coli. vIL-6 made in eukaryotic cells is N-linked
glycosylated at two sites, N78 and N89. Based on mutagen-
esis, only the N89 site is functionally important in engaging
the gp130 receptor, JAK/STAT signaling, and stimulation
of cell proliferation. The importance of N-linked glycosyla-
tion was confirmed by the use of the inhibitor TM, a fungal
UDP-GlcNAc–like product that blocks the production of
the Glc3Man9GlcNAc2 precursor oligosaccharide required
for N-linked glycosylation initiation. In stark contrast,
the human cellular homologue, hIL-6, does not require
Figure 9. N-linked glycosylation is not required for hIL-6 receptor
binding, STAT signaling or cytokine-dependent B9.11 cell prolifera-
tion. (A) Calibration of quantities of hIL-6 and N-linked glycosylation
site mutants secreted from transfected HKB5/B5 cells. ELISA plates
were coated with polyclonal goat antibody to hIL-6, and hIL-6 was
quantitated with monoclonal mouse antibody to hIL-6 conjugated to
HRP. All the hIL-6 supernatants contained 100 ng/ml hIL-6 protein.
(B) Binding to sgp130 in the presence or absence of soluble IL-6R .
ELISA plates were coated with sgp130. Culture supernatants mixed
with soluble IL-6R , or untreated, were assessed for binding to sgp130
by ELISA. (C) Supernatants from HKB5/B5 cells transfected with wild-
type hIL-6 or N-linked glycosylation site mutants were assessed for
their capacity to activate a STAT1-responsive reporter, pGAS3/Luc.
(D) B9.11 cell proliferation assay in response to wild-type and N-linked
glycosylation site mutants of hIL-6.Dela Cruz et al. 511
N-linked glycosylation for optimal function. Mutagenesis of
the single site N73 on hIL-6 that is N-linked glycosylated
did not affect IL-6R –dependent gp130 receptor binding,
JAK/STAT signaling, or stimulation of B cell proliferation,
even with the additional removal of all the O-glycans in
hIL-6. These results demonstrate that the KSHV-encoded
cytokine not only relies on N-linked glycosylation status for
optimal biological function, but also for distinguishing itself
from its human homologue.
We also found that the fully glycosylated form of hIL-6
is  100 times more potent in stimulating IL-6–dependent
cell proliferation when compared with the fully glycosyl-
ated form of vIL-6. Burger et al. (3) previously reported
that equal amounts of unglycosylated hIL-6 was 5,000
times more potent than the vIL-6 counterpart when pro-
teins were made in bacteria. These differences in biological
potency when comparing glycosylated and unglycosylated
forms of the two IL-6 homologues can be accounted for by
our finding that N-linked glycosylation is required for the
optimal function of vIL-6, and that vIL-6 expressed in E.
coli has minimal function. The difference in potency be-
tween fully glycosylated forms of hIL-6 and vIL-6 in stim-
ulating cell proliferation might be explained by receptor af-
finity or the quality of downstream signaling events.
Figure 10. Unglycosylated and fully glycosylated forms of hIL-6 proteins have
similar biological potency. (A) Electrophoretic mobility of glycosylation site mutants
of hIL-6. Lane 1, wild-type hIL-6; lane 2, T6A hIL-6; lane 3, T166A hIL-6; lane
4, T170A/T171A hIL-6; lane 5, T166A/T170A/T171A hIL-6 (lacking all O-glycans);
lane 6, T166A/T170A/T171A/N73K hIL-6 (lacking all O- and N-glycans). (B) Elec-
trophoretic mobility of hIL-6 glycoforms expressed in HKB5/B5 cells. Lanes 1–2
and 7, wild-type hIL-6; lane 3, supernatant from pcDNA3.1-transfected cells; lane
4, hIL-6 produced in the presence of TM; lane 5, hIL-6 produced in the presence
of monensin; lane 6, hIL-6 produced in the presence of both monensin and TM.
(C) ELISA assay for the binding to gp130/IL-6R  of hIL-6, hIL-6 made in the
presence of monensin and TM, and hIL-6 mutant lacking both O- and N-glycans
(T166A/T170A/T171A/N73K). (D) B9.11 proliferative activity of wild-type hIL-6
( ), O-glycan lacking hIL-6 mutant (T166A/T170A/T177A;  ), or fully unglyco-
sylated hIL-6 mutant (T166A/T170A/T171A/N73K;  ). (E) B9.11 proliferation
assay using hIL-6 expressed in the absence of inhibitors ( ), the presence of mo-
nensin ( ), the presence of TM ( ), or the presence of both inhibitors ( ). Equal
amounts of hIL-6 preparations were used in the above experiments as assessed by
hIL-6–specific ELISA.N-linked Glycosylation of Viral and Human IL-6 512
Examples of Functional Importance of N-linked Glycosylation
of Other Secreted Cellular Cytokines and Growth Factors. Al-
though this report appears to be the first to demonstrate
the difference of N-linked glycosylation of closely related
viral and cellular cytokine homologues, several examples
illustrate the importance of N-linked sugar modifications
on the function of cellular-secreted factors. Glycosylation
can affect protein stability, specific receptor interaction,
and biological activity. For instance, N-linked sugars on
human IL-5 have been shown to be important for its ther-
mostability when the protein was incubated at 70 C for
30 min. The de-N-glycosylated hIL-5 was less biologi-
cally active after heating (23). Two forms of recombinant
IFN-  are currently used as treatment for multiple sclero-
sis. The fully N-glycosylated form (IFN- -1a) is at least
10 times more biologically active than the nonglyco-
sylated form (IFN- -1b). This difference has been attrib-
uted to the stabilizing effect of the carbohydrate on the
protein structure (24). Recombinant G-CSF is also clini-
cally available in two different forms: lenograstim, the gly-
cosylated form, is more active at increasing absolute neu-
trophil count in vivo than filgrastim, the deglycosylated
form, an effect also attributable to better protein stability
(25). Another example is human erythropoietin, a heavily
glycosylated protein with multiple glycoforms. Although
N-deglycosylated erythropoietin exhibits full biological
activity and potency in vitro, its activity in vivo that in-
volves anchoring terminal sialic acids is significantly de-
creased (26).
Hypotheses to Account for the Functional Importance of
N-linked Glycosylation in vIL6. We have considered two
hypotheses to account for the essential role of glycosylation
of N89. First, N-linked glycosylation of vIL-6 might be re-
quired for optimal binding to gp130, either via sugar–sugar
or sugar–protein interactions. Gp130 is heavily glycosylated
at 9 of the 11 potential N-linked sites (27). Thus, there is
ample opportunity for sugar–sugar interaction. A second
but not mutually exclusive explanation is the requirement
of N-linked sugars in N89 for proper folding of vIL-6 into
a conformation optimal for interaction with gp130.
The crystal structure of vIL-6 in a complex with the
gp130 receptor has been solved (11) and may help to dis-
tinguish these alternatives. To achieve the 2.4 Å X-ray
cocrystal structure resolution, it was necessary to use non-
glycosylated forms of the vIL-6 and gp130 proteins pro-
duced in insect cells in the presence of the inhibitor TM.
Therefore, N-linked glycosylation is not absolutely re-
quired for vIL-6 and gp130 interaction. The complex as-
sumes a tetrameric arrangement comprising two vIL-6 pro-
teins and two human gp130 receptors. Each vIL-6 contacts
two different gp130 molecules and each gp130 interacts
with two vIL-6 molecules, all through structurally distinct
binding surfaces (Fig. 12; reference 11). Residues in vIL-6
designated site II interact with domains 2 and 3 (D2D3) of
gp130 comprising a cytokine-binding homology region. A
second vIL-6 region designated site III interacts with the
Figure 11. Fully glycosylated hIL-6 is more potent than the KSHV IL-6
counterpart. 10-fold serially diluted supernatants from HKB5/B5 cells
transfected with plasmids encoding wild-type hIL-6 or vIL-6, all starting
at 10 ng/ml, were assessed for their capacity to stimulate proliferation of
B9.11 cells.
Figure 12. Location of the N-linked glycosylation sites of KSHV-
encoded IL-6 on the schematic representation of the cocrystal structure
of vIL-6 and gp130. Carbon backbone model of vIL-6 and soluble gp130
is shown as a tetrameric complex based on previous crystal structure
work, shown in side (A) and tilted view (B; reference 11). A shows site I
of vIL-6, which is not a contact site with gp130, but corresponds to a site
where hIL-6 interacts with IL6-R . B shows one vIL-6 site II (black
dotted circle) in contact with D2D3 sites of gp130 molecule (green), and
vIL-6 site III (red dotted circle) in contact with D1 site of a second gp130
molecule (blue). N78 (yellow) and N89 (red) are highlighted as space-
filling residues and are shown to occupy site I, but not sites II or III. The
figure was prepared using the RasMol program (v2.7.1).Dela Cruz et al. 513
NH2-terminal D1 Ig-like activation domain of a second
gp130 molecule. These interactions are required for assem-
bly of a higher order activation complex important for sig-
nal transduction (28, 29). It is important to note that the
two N-linked glycosylation sites of vIL-6 are located close
to each other, but are outside of sites II and III important
for cytokine–gp130 receptor interaction (Fig. 12).
vIL-6 has an unused site I facet not occupied by gp130.
The equivalent site in hIL-6 interacts with the IL-6R .
N78 and N89 are located in the vicinity of site I. The in-
teraction of IL-6R  with site I of hIL-6 is thought to alter
the conformation of cellular cytokine to enable it to bind
to gp130 (13, 28). It is notable that N78 and N89 of vIL-6
are located in the vicinity of site I. Therefore, N-linked
glycosylation of N89 may substitute for an interaction with
IL-R  and change the conformation of the viral cytokine
so that it binds gp130. In support of this idea, monoclonal
antibodies directed against the epitope D81 to C93 imbed-
ded in the hypothetical site I of vIL-6 and located outside
the cytokine-gp130 interface neutralize the viral cytokine
by interfering with vIL-6 interaction with sgp130 (30).
These monoclonal antibodies were postulated to induce
conformation changes in vIL-6 that abrogated its function.
Our results, taken together with the crystal structure and
the effect of neutralizing antibodies, are most consistent
with the hypothesis that the N-linked sugars on N89 are
critical to establishing the proper conformation of vIL-6
needed to interact with gp130. A potentially important bi-
ological consequence of N-linked glycosylation of vIL-6
might be to extend its tropism to cells that contain gp130
and lack IL-6R . For instance, although both B cells and
endothelial cells can be infected by KSHV, only B cells and
not endothelial cells express IL-6R . Further work is
needed to characterize the nature of the N-linked sugar
side chains and to study the mechanism by which they in-
fluence vIL-6 folding.
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